Ischemic heart failure is a major public health burden in western societies. Although technical advancements have improved recascularization of ischemic heart tissue in recent years, data on functional improvement concerning the left ventricle suggest a need for optimization of pharamcological therapie. The growth hormone erythropoietin beta has been shown to improve heart function in various animal models of ischemic heart disease.
Conditions
Interventions
Product Name: neorecormon
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Epoetin beta
Concentration unit: IU international unit(s)
Concentration type: up to
Concentration number: 100
Sponsors
Franz Volhard Clinic, Charite Campus Buch
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: patients after succesful percutaneous, coronary interventions, signs of ischemic heart failure and mild anemia. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: acute cardiogenic shock, contraindictaiosn for MRI, cancer, iron deficiency, pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To test the effect of a once weekly dose of erythropietin on left ventricular remodelling after coronary intervention.;Secondary Objective: to test for heart failure parameters, bnp levels, exercise tolerance, myocardial fibrosis;Primary end point(s): global ejection fraction in MRI and Echo | — |
Countries
Germany
Outcome results
None listed